Shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the seven brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $52.50.
A number of equities research analysts have commented on TGTX shares. Zacks Research cut TG Therapeutics from a “hold” rating to a “strong sell” rating in a report on Friday, May 1st. JPMorgan Chase & Co. decreased their price target on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating on the stock in a report on Monday, February 2nd. Wall Street Zen cut TG Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. HC Wainwright reissued a “buy” rating and set a $70.00 price target on shares of TG Therapeutics in a report on Wednesday. Finally, Weiss Ratings raised TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, May 1st.
View Our Latest Report on TG Therapeutics
TG Therapeutics Price Performance
TG Therapeutics (NASDAQ:TGTX – Get Free Report) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.The company had revenue of $204.92 million during the quarter, compared to the consensus estimate of $200.33 million. During the same period in the prior year, the business posted $0.03 earnings per share. TG Therapeutics’s revenue for the quarter was up 69.5% compared to the same quarter last year. Sell-side analysts anticipate that TG Therapeutics will post 1.31 earnings per share for the current year.
Institutional Investors Weigh In On TG Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Danske Bank A S purchased a new position in shares of TG Therapeutics during the third quarter valued at about $25,000. Optiver Holding B.V. grew its position in TG Therapeutics by 3,485.7% in the third quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 732 shares in the last quarter. Bessemer Group Inc. grew its position in TG Therapeutics by 117.1% in the third quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 486 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in TG Therapeutics by 51.9% in the first quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 365 shares in the last quarter. Finally, Hantz Financial Services Inc. grew its position in TG Therapeutics by 82.7% in the fourth quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 560 shares in the last quarter. 58.58% of the stock is owned by institutional investors.
About TG Therapeutics
TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.
In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.
Featured Articles
- Five stocks we like better than TG Therapeutics
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
